2Suppliers
11Customers
2Debt Items
20Related Chains

Source-Backed Evidence Depth

ImageneBio, Inc. (IMA) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.

16Total relationships
2Distinct source URLs
5High confidence
0.733Average confidence
2026-09-13Latest database update
ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.

ImageneBio, Inc. Suppliers

TickerNameConfidenceEvidence
HUTCHMED HUTCHMED 90% Our licenses from Hutchmed and WuXi Biologics are limited to intellectual property rights owned or controlled by such licensors.
WUXI-BIOLOGICS WUXI-BIOLOGICS 90% Our licenses from Hutchmed and WuXi Biologics are limited to intellectual property rights owned or controlled by such licensors.

ImageneBio, Inc. Customers

TickerNameConfidenceEvidence
NKTR Nektar Therapeutics 72% Reciprocal relationship from NKTR graph: Reciprocal relationship from IMA graph: ntures or collaborations, or enter into additional licensing arrangements with third parties that we believe will comp…
NKTR Nektar Therapeutics 72% ntures or collaborations, or enter into additional licensing arrangements with third parties that we believe will complement or augment our development and commercialization efforts with respect to I…
SNYNF Sanofi 72% Reciprocal relationship from SNYNF graph: Reciprocal relationship from IMA graph: Reciprocal relationship from SNYNF graph: Reciprocal relationship from IMA graph: Reciprocal relationship from SNYNF …
SNYNF Sanofi 72% ntures or collaborations, or enter into additional licensing arrangements with third parties that we believe will complement or augment our development and commercialization efforts with respect to I…
CELEXOR-BIO-INC CELEXOR-BIO-INC 62% (the “Celexor Agreement”) with Celexor Bio, Inc. (“Celexor”). Legacy Inmagene granted Celexor an exclusive royalty-bearing license to develop, manufacture, and commercialize any and all products and …
HONG-KONG-LIMITED HONG-KONG-LIMITED 62% nt timelines. Increased development costs and extended development timelines could place us at a competitive disadvantage compared to companies operating in regions with more favorable trade relation…
HUTCHINSON-MEDIPHARMA-LIMITED HUTCHINSON-MEDIPHARMA-LIMITED 62% authorities of individual EU Member States or comparable foreign regulatory authorities to perform additional preclinical studies and clinical trials or to modify any of our manufacturing processes o…
HUTCHMED-LIMITED HUTCHMED-LIMITED 62% authorities of individual EU Member States or comparable foreign regulatory authorities to perform additional preclinical studies and clinical trials or to modify any of our manufacturing processes o…
IKENA-ONCOLOGY-INC IKENA-ONCOLOGY-INC 62% Time, (i) each ordinary share and preferred share of Legacy Inmagene (each such share, a “Legacy Inmagene Share”) held as treasury shares immediately prior to the First Effective Time were canceled a…
NON-OX40-DIVESTITURE-MIRAGENE-CO NON-OX40-DIVESTITURE-MIRAGENE-CO 62% Time, (i) each ordinary share and preferred share of Legacy Inmagene (each such share, a “Legacy Inmagene Share”) held as treasury shares immediately prior to the First Effective Time were canceled a…
PRESENTATION-IMAGENEBIO-INC PRESENTATION-IMAGENEBIO-INC 62% $ 3,051 Deferred offering costs included in accounts payable and accrued expenses and other current liabilities $ — $ 3,602 The accompanying notes are an integral part of these unaudited condensed co…

ImageneBio, Inc. Debt Obligations

InstrumentDescriptionConfidenceEvidence
IMA-DEBT Debt stack $2.4M 90% Market cache reports total debt of $2.4M.
IMA-DEBT-10227 Xbrl Convertible 90% xbrl convertible detail from xbrl 2025-12-31.

ImageneBio, Inc. Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for ImageneBio, Inc..

ImageneBio, Inc. Ownership

HolderNameConfidenceEvidence
IMA-OWNER-BVF-INC-IL BVF INC/IL 90% 13F overlay lists BVF INC/IL as top holder; 38 tracked holders.

ImageneBio, Inc. Extended Supply Chain Network

TickerNameChain IndexHopsRelationship Types
CTMX CytomX Therapeutics, Inc. 100.00 2
GRDX GridAI Technologies Corp. 100.00 2
CALC CalciMedica, Inc. 100.00 2
BLRX BioLineRx Ltd. 100.00 2
CYTOF Altamira Therapeutics Ltd. 100.00 2
SVA Sinovac Biotech Ltd. 100.00 2
ANL Adlai Nortye Ltd. 100.00 2
REGN Regeneron Pharmaceuticals, Inc. 100.00 2
CBIO Crescent Biopharma, Inc. 100.00 2
ANRO Alto Neuroscience, Inc. 100.00 2
CCEP Coca-Cola Europacific Partners PLC 100.00 2
DSGN Design Therapeutics, Inc. 100.00 2
AZN AstraZeneca PLC 100.00 2
ALXO ALX Oncology Holdings Inc. 100.00 2
DBVTF DBV TECHNOLOGIES 100.00 2
BIOA BioAge Labs, Inc. 100.00 2
EDIT Editas Medicine, Inc. 100.00 2
CYTK Cytokinetics, Incorporated 100.00 2
ATOS Atossa Therapeutics, Inc. 100.00 2
ADAG Adagene Inc. 100.00 2
🔐
IMA
Unlock IMA Supply Chain Data
Verified relationships include:
HUTCHMEDHUTCHMEDSupplier90%
WUXI-BIOLOGICSWUXI-BIOLOGICSSupplier90%
NKTRNektar TherapeuticsCustomer72%
NKTRNektar TherapeuticsCustomer72%
+12 more relationships locked
Subscribe — View plans →